John Neis
CIK 1167426 · last filed 2026-07-08
John Neis is a corporate insider who has filed 23 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for CLRB, was dated Jul 8, 2026. Across all open-market trades the lifetime net is −$105.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $12 across reported positions. 7 SEC filings were submitted jointly with Venture Investors LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TTPY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
MADISON, WI 53719
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CLRB | Director | 10 | $1.21 | $12 | -$732 | 7 | 2026-07-08 |
| Cellectar Biosciences, Inc. (CLRBZ) Delisted | Director | 626,103 | $0.12 | $74.5K | $488.9K | 8 | 2021-03-19 |
| Cellectar Biosciences, Inc. (CLRB.W) Delisted | Director | 493,715 | — | — | $1.01M | 4 | 2016-07-06 |
| Cellectar Biosciences, Inc. (CLRB.Z) Delisted | Director | 297,984 | — | — | $497.7K | 1 | 2016-04-21 |
| TomoTherapy Inc (TOMO) Delisted | Director | 926,160 | — | — | -$1.00M | 1 | 2008-02-28 |
| TomoTherapy Inc (TTPY) Delisted | Director | 983,194 | — | — | -$106.69M | 2 | 2007-10-18 |
Recent Filings
23 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-08 | CLRB | Grant (A) | — | $0 | EDGAR |
| 2025-12-16 | CLRB | Sell (S) | −198 | -$732 | EDGAR |
| 2025-02-18 | CLRB | Grant (A) | — | $0 | EDGAR |
| 2024-06-18 | CLRB | Grant (A) | — | $0 | EDGAR |
| 2023-06-28 | CLRB | Grant (A) | — | $0 | EDGAR |
| 2022-08-01 | CLRB | Grant (A) | — | $0 | EDGAR |
| 2021-07-02 | CLRB | Grant (A) | — | $0 | EDGAR |
| 2021-03-19 | Cellectar Biosciences, Inc. (CLRBZ) Delisted | Sell (S) | — | $0 | EDGAR |
| 2021-03-16 | Cellectar Biosciences, Inc. (CLRBZ) Delisted | Sell (S) | — | $0 | EDGAR |
| 2020-06-25 | Cellectar Biosciences, Inc. (CLRBZ) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.